A recent small RCT demonstrates weight loss raises testosterone more than TRT, in patients who are obese.
Link to full study:
Paper · Reprod Biol Endocrinol · 2025Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Conclusion: The results of this study suggest that TZP is effective in improving both metabolic parameters, ED, and gonadal hormone levels in patients with obesity and metabolic hypogonadism. These findings position TZP as a promising treatment for obese patients with functional hypogonadism arising from metabolic-related alterations.pmc.ncbi.nlm.nih.govQuoted:
“A total of 83 patients with obesity (mean age 55.3 ± 5.5 years) were included in the study, divided into three groups: Group A (28 patients, mean age 56.3 ± 4.7 years), Group B (30 patients, mean age 55.1 ± 5.2 years), and Group C (25 patients, mean age 54.0 ± 6.5 years).”
“Group A received 2.5 mg of TZP [tirzepatide] weekly for the first month, with the dose increased to 5 mg from the second month; Group B received no pharmacological treatment: Group C received transdermal testosterone.”
“After 2 months, Group A showed significantly greater reductions in body weight, WC [waist circumference], BES score, and fat mass, along with a notable increase in LM [lean mass] and IIEF-5 score compared to Groups B and C. Additionally, Group A exhibited significantly higher serum levels of LH, FSH, SHBG, TT, fT, and bioT, while E2 levels were significantly lower than both Groups B and C.”
#trtHD #testosteroneHD #weightlossHD #aromataseHD #visceralfatHD










